New Delhi [India], September 12 (ANI): The Competition Commission of India (CCI) has approved the proposed combination involving the acquisition of 20 per cent of the issued and paid-up equity share capital of Piramal Pharma Limited (Pharma Co) by CA Clover Intermediate II Investments (Curie